As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at medical devices & supplies - diversified stocks, starting with Boston Scientific (NYSE: BSX).

The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies. However, the capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers.

The 5 medical devices & supplies - diversified stocks we track reported a satisfactory Q3. As a group, revenues beat analysts’ consensus estimates by 1.8% while next quarter’s revenue guidance was 4.5% below.

In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results.

Boston Scientific (NYSE: BSX)

Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE: BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties.

Boston Scientific reported revenues of $5.14 billion, up 1.4% year on year. This print exceeded analysts’ expectations by 1.4%. Despite the top-line beat, it was still a slower quarter for the company with revenue guidance for next quarter missing analysts’ expectations significantly and a miss of analysts’ full-year EPS guidance estimates.

"This has been a challenging year for Boston Scientific and I'm proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation."

Boston Scientific delivered the slowest revenue growth among its peers. The market seems disappointed with the results as the stock is down 3.3% since reporting and currently trades at $43.56.

Is now the time to buy Boston Scientific? Access our full analysis of the earnings results here, it’s free.

Best Q3: Neogen (NASDAQ: NEOG)

Founded in 1981 and operating at the intersection of food safety and animal health, Neogen (NASDAQ: NEOG) develops and manufactures diagnostic tests and related products to detect dangerous substances in food and pharmaceuticals for animal health.

Neogen reported revenues of $222.8 million, up 6.5% year on year, outperforming analysts’ expectations by 7%. The business had a very strong quarter with a beat of analysts’ EPS estimates and full-year revenue guidance meeting analysts’ expectations.

Neogen scored the biggest analyst estimate beat in the group. The market seems content with the results as the stock is up 1.2% since reporting. It currently trades at $12.11.

Is now the time to buy Neogen? Access our full analysis of the earnings results here, it’s free.

Weakest Q3: Stryker (NYSE: SYK)

With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE: SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.

Stryker reported revenues of $6.52 billion, up 7.6% year on year, falling short of analysts’ expectations by 1.5%. It was a softer quarter as it posted a miss of analysts’ organic revenue estimates and a slight miss of analysts’ full-year EPS guidance estimates.

Stryker delivered the weakest performance against analyst estimates of the whole group. As expected, the stock is down 1.5% since the results and currently trades at $307.11.

Read our full analysis of Stryker’s results here.

Abbott Laboratories (NYSE: ABT)

With roots dating back to 1888 when founder Dr. Wallace Abbott began producing precise, dosage-form medications, Abbott Laboratories (NYSE: ABT) develops and sells a diverse range of healthcare products including medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals.

Abbott Laboratories reported revenues of $13.01 billion, up 14.5% year on year. This print met analysts’ expectations. Aside from that, it was a mixed quarter as its performance in some other areas of the business was disappointing.

Abbott Laboratories achieved the fastest revenue growth among its peers. The stock is up 6.6% since reporting and currently trades at $109.20.

Read our full, actionable report on Abbott Laboratories here, it’s free.

Baxter (NYSE: BAX)

With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.

Baxter reported revenues of $2.98 billion, up 5% year on year. This result topped analysts’ expectations by 2.3%. It was an exceptional quarter as it also produced a beat of analysts’ EPS estimates.

The stock is flat since reporting and currently trades at $25.39.

Read our full, actionable report on Baxter here, it’s free.

Market update

Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.

Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.

By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.

Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.